Pamorelin (Triptorelin)

Triptorelin, the active ingredient in Pamorelin, is a GnRH agonist presented as a 0.1 mg/3 ml solution for subcutaneous injection use. It is employed in the management of hormone‑dependent conditions such as prostate cancer, endometriosis and uterine fibroids in adults.

GNH USA supplies Pamorelin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Pamorelin is a GnRH‑agonist that modulates the hormonal axis in several disease families. - Prostate cancer: provides androgen suppression to slow tumor progression. - Endometriosis: induces a hypo‑estrogenic state that reduces pelvic pain and lesion growth. - Uterine fibroids: lowers estrogen levels to decrease fibroid size and related bleeding.

Adverse reactions to Pamorelin are reported across a spectrum of frequency.

Common Side Effects: - Hot flashes: transient warmth and sweating. - Injection site pain: mild to moderate discomfort at the injection site. - Headache: occasional tension‑type headache. - Fatigue: general tiredness. - Nausea: mild, self‑limiting gastrointestinal upset.

Serious or Rare Side Effects: - Cardiovascular events: myocardial infarction or stroke. - Severe allergic reaction: anaphylaxis or angio‑edema. - Bone loss: accelerated osteoporosis leading to fractures. - Hormonal crisis: acute adrenal insufficiency in vulnerable patients. - Pituitary apoplexy: sudden hemorrhage within the pituitary gland.

When prescribing Pamorelin, clinicians should consider several safety aspects. - Cardiovascular assessment: evaluate history of heart disease before initiating therapy. - Bone health monitoring: perform baseline densitometry and repeat as needed. - Hormone‑dependent tumor surveillance: watch for flare‑up of hormone‑sensitive lesions. - Pregnancy and lactation: avoid use in women who are pregnant or breastfeeding. - Storage: Store below 25°C: keep in the original pack, protect from moisture.

Triptorelin may interact with other medicines that influence hormonal or cardiovascular status.

Major Interactions (Avoid): - Anti‑androgens: may blunt the intended androgen‑suppression effect. - CYP450 inducers: can alter the metabolic clearance of concomitant drugs.

Moderate Interactions (Monitor Closely): - Anticoagulants: increased risk of bleeding with injection‑site bruising. - Hormone replacement therapy: may require dose adjustments. - GnRH antagonists: concurrent use can produce unpredictable hormone levels.